Treating metastatic breast cancer with systemic chemotherapies: current trends and future perspectives.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Clinical Journal of Oncology Nursing

• Publication date

  2012-03-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1188/12.CJON.E33-E43PMID 22459535
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

  2012cited by this paper
• Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro

  2012cited by this paper
• Cancer statistics, 2012

  2012cited by this paper
• Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

  2011cited by this paper
• Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

  2011cited by this paper
• Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer.

  2011cited by this paper
• Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

  2011cited by this paper
• Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features

  2011cited by this paper
• Triple-negative breast cancer: an unmet medical need.

  2011cited by this paper
• Ixabepilone, a Novel Microtubule-Targeting Agent for Breast Cancer, Is a Substrate for P-Glycoprotein (P-gp/MDR1/ABCB1) but not Breast Cancer Resistance Protein (BCRP/ABCG2)

  2011cited by this paper
• Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor

  2011cited by this paper
• Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells

  2011cited by this paper
• Novel treatment approaches for triple-negative breast cancer.

  2010cited by this paper
• Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

  2010cited by this paper
• Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials

  2010cited by this paper
• Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

  2010cited by this paper
• Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.

  2010cited by this paper
• Poly (ADP-Ribose) Polymerase as a Novel Therapeutic Target in Cancer

  2010cited by this paper
• Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer

  2010cited by this paper
• Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

  2010cited by this paper
• Use of Trastuzumab in HER2-positive Metastatic Breast Cancer beyond Disease Progression: A Systematic Review of Published Studies

  2010cited by this paper
• Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer

  2010cited by this paper
• Maintenance of clinical efficacy following dose reduction of ixabepilone plus capecitabine (Cape) in patients (pts) with anthracycline (A) and taxane (T) pretreated (pretx) metastatic breast cancer (MBC): A retrospective analysis of pooled data from two phase III clinical studies (046/048).

  2010cited by this paper
• Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

  2010cited by this paper
• Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients.

  2010cited by this paper
• Triple-negative breast cancer.

  2010cited by this paper
• Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.

  2010cited by this paper
• Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer.

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

  2010cited by this paper
• Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer.

  2010cited by this paper
• Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer.

  2010cited by this paper
• Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer.

  2009cited by this paper
• Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

  2009cited by this paper
• Single agent versus combination chemotherapy for metastatic breast cancer.

  2009cited by this paper
• Proactive management of adverse events maintains the clinical benefit of ixabepilone.

  2009cited by this paper
• Current concepts of anthracycline cardiotoxicity : pathogenesis, diagnosis and prevention

  2009cited by this paper
• Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

  2009cited by this paper
• Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer.

  2009cited by this paper
• Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.

  2009cited by this paper
• Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1

  2009cited by this paper
• Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.

  2009cited by this paper
• American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.

  2009cited by this paper
• The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure.

  2009cited by this paper
• International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy

  2009cited by this paper
• The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: a systematic review.

  2009cited by this paper
• Preclinical efficacy spectrum and pharmacokinetics of ixabepilone

  2008cited by this paper
• Carboplatin plus gemcitabine repeating doublet therapy in recurrent breast cancer.

  2008cited by this paper
• Candidate mechanisms for capecitabine-related hand-foot syndrome.

  2008cited by this paper
• Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.

  2008cited by this paper
• TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer

  2008cited by this paper
• Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.

  2008cited by this paper
• A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

  2008cited by this paper
• Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

  2008cited by this paper
• Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.

  2008cited by this paper
• Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel

  2008cited by this paper
• Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.

  2008cited by this paper
• A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer.

  2008cited by this paper
• Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.

  2008cited by this paper
• Gemcitabine and Carboplatin in Intensively Pretreated Patients with Metastatic Breast Cancer

  2008cited by this paper
• Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

  2008cited by this paper
• Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of β‐tubulins

  2007cited by this paper
• Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.

  2007cited by this paper
• Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.

  2007cited by this paper
• Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

  2007cited by this paper
• Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.

  2007cited by this paper
• Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.

  2007cited by this paper
• Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes.

  2007cited by this paper
• Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.

  2007cited by this paper
• Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas)

  2007cited by this paper
• Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.

  2007cited by this paper
• Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.

  2007cited by this paper
• Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.

  2007cited by this paper
• Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.

  2007cited by this paper
• Gemcitabine: monochemotherapy of breast cancer.

  2006cited by this paper
• Management of hand-foot syndrome induced by capecitabine

  2006cited by this paper
• Peripheral neuropathy induced by microtubule-stabilizing agents.

  2006cited by this paper
• Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.

  2006cited by this paper
• Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).

  2006cited by this paper
• Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

  2006cited by this paper
• βIII-Tubulin Induces Paclitaxel Resistance in Association with Reduced Effects on Microtubule Dynamic Instability*

  2005cited by this paper
• A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.

  2005cited by this paper
• The Role of the BRCA1 Tumor Suppressor in DNA Double-Strand Break Repair

  2005cited by this paper
• Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer.

  2005cited by this paper
• Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer.

  2005cited by this paper
• The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells

  2004cited by this paper
• Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).

  2004cited by this paper
• Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.

  2004cited by this paper
• Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy.

  2003cited by this paper
• Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.

  2003cited by this paper
• Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.

  2002cited by this paper
• BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.

  2001cited by this paper
• Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma

  2001cited by this paper
• Single-Agent Gemcitabine Is Active in Previously Treated Metastatic Breast Cancer

  2001cited by this paper
• Multicenter, Phase II study of capecitabine in taxane‐pretreated metastatic breast carcinoma patients

  2001cited by this paper
• Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.

  2001cited by this paper
• Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.

  2000cited by this paper
• Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.

  1999cited by this paper

• Simultaneously metastatic cholangiocarcinoma and small intestine cancer from breast cancer misdiagnosed as primary cholangiocarcinoma: A case report

  2023cites this paper
• Isolation of potassium salt of oxadiazole-2-thione and in vitro anticancer activities of its Cu(II) and Zn(II) complexes against MDA-MB-231 human breast carcinoma cells.

  2023cites this paper
• Rare common bile duct metastasis of breast cancer: A case report and literature review

  2021cites this paper
• In vitro Evaluation of Isatin derivatives as Potent Anti-Breast Cancer Agents against MCF-7, MDA MB 231, MDA-MB 435 and MDA-MB 468 Breast Cancers cell lines: A Review.

  2021cites this paper
• Myosteatosis at diagnosis is adversely associated with 2-year survival in women with estrogen receptor-negative metastatic breast cancer

  2021cites this paper
• Number 2 February 15 , 2021 ABOUT COVER

  2021cites this paper
• Comparative effects of selected plant polyphenols, gallic acid and epigallocatechin gallate, on matrix metalloproteinases activity in multidrug resistant MCF7/DOX breast cancer cells.

  2016cites this paper
• Unusual sites of metastasis of breast carcinoma to gallbladder and colon

  2016cites this paper
• Lobular Carcinoma of the Breast with Gastrointestinal Metastasis

  2015cites this paper
• Oncology Nursing Support for Safe and Effective Use of Eribulin in Metastatic Breast Cancer

  2014cites this paper
• Priming cancer cells for drug resistance: role of the fibroblast niche

  2014cites this paper
• The endogenous oxindole isatin induces apoptosis of MCF‑7 breast cancer cells through a mitochondrial pathway.

  2014cites this paper
• Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells

  2014cites this paper
• Eribulin mesylate: A new therapeutic option for metastatic breast cancer

  2013cites this paper
• Cryotherapy protocols for metastatic breast cancer after failure of radical surgery.

  2013cites this paper
• Altered TUBB3 expression contributes to the epothilone response of mitotic cells

  2013cites this paper
• Pertuzumab in Metastatic Breast Cancer

  2012cites this paper
• Cancer Management and Research Dovepress Management of Patients with Hormone Receptor– Positive Breast Cancer with Visceral Disease: Challenges and Treatment Options

  year unknowncites this paper